Abivax (ABVX) Tax Provisions (2025 - 2026)
Abivax (ABVX) posted quarterly Tax Provisions of -$266930.0 for Q1 2026, up 96.05% quarter-over-quarter from -$6.8 million in Q4 2025.
Abivax (ABVX) Tax Provisions (2025 - 2026) Analysis & Trends
Abivax's Tax Provisions history runs 2 years deep, the most recent figure standing at -$266930.0 for Q1 2026.
- In Q1 2026, Tax Provisions changed N/A year-over-year to -$266930.0; the TTM figure through Mar 2026 stood at -$7.0 million (changed N/A YoY), while the FY2025 annual figure was -$6.8 million, changed N/A from the prior year.
- Tax Provisions for Q1 2026 stood at -$266930.0, up from -$6.8 million in the prior quarter.
- The five-year high for Tax Provisions was -$266930.0 in Q1 2026, with the low at -$6.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Abivax | 9.39 Bn | 9.39 Bn | - | -266,930.01 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -266,930.01 |
| Dec 31, 2025 | -6.75 Mn |